Search Results - "Elias, A.D"

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours by Schöffski, P, Adkins, D, Blay, J.-Y, Gil, T, Elias, A.D, Rutkowski, P, Pennock, G.K, Youssoufian, H, Gelderblom, H, Willey, R, Grebennik, D.O

“…Abstract Background Cixutumumab (IMC-A12), a fully human immunoglobulin G1 (IgG1) monoclonal antibody, exerts preclinical activity in several sarcoma models…”
Get full text

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials by Marczyk, M., Mrukwa, A., Yau, C., Wolf, D., Chen, Y.-Y., Balassanian, R., Nanda, R., Parker, B.A., Krings, G., Sattar, H., Zeck, J.C., Albain, K.S., Boughey, J.C., Liu, M.C., Elias, A.D., Clark, A.S., Venters, S.J., Shad, S., Basu, A., Asare, S.M., Buxton, M., Asare, A.L., Rugo, H.S., Perlmutter, J., DeMichele, A.M., Yee, D., Berry, D.A., Veer, L. van’t, Symmans, W.F., Esserman, L., Pusztai, L.

“…Difference in pathologic complete response (pCR) rate after neoadjuvant chemotherapy does not capture the impact of treatment on downstaging of residual cancer…”
Get full text

A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (dox) with or without olaratumab (IMC-3G3), a human anti–platelet-derived growth factor (pdgfr ) monoclonal antibody, in advanced soft tissue sarcoma (sts) by Tap, W., Jones, R.L., Chmielowski, B., Elias, A.D., Adkins, D., Van Tine, B.A., Agulnik, M., Cooney, M., Livingston, M.B., Pennock, G., Qin, A., Shahir, A., Ilaria, R., Conti, I., Schwartz, G.

Get full text

A Phase II Clinical Trial of ENMD-2076 in Metastatic Triple-Negative Breast Cancer: Translating a P53-Based Biomarker from Bench to Bedside by Diamond, J.R., Tan, A.C., Pitts, T.M., van Bokhoven, A., Aisner, D., Elias, A.D., Borges, V.F., Miller, K.D., Eckhardt, S.G., Tentler, J.J.

Get full text

A Surrogate-Assisted Genetic Algorithm Framework to Discover Peptides Against COVID-19 Virus by Silva, Elias A.D., Palmeira, Lucas S., Garcia-Junior, Marcelo A., Martins, Luiz G.A., Jin, Yaochu, Andrade, Bruno S., Sabino-Silva, Robinson, Carneiro, Murillo G.

“…The design of peptides capable of inhibiting the SARS-CoV-2 viral infection has been considered one of the potential strategies to reduce the transmission of…”
Get full text

Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC) by Elias, A.D., Skarin, A.T., Leong, T., Mentzer, S., Strauss, G., Lynch, T., Shulman, L., Jacobs, C., Abner, A., Baldini, E.H., Frei, E., Sugarbaker, D.J.

“…Introduction: Neoadjuvant therapy in patients with Stage IIIA NSCLC is associated with a 50–70% resection rate and a 3–5 year survival of 20–32%, but few…”
Get full text

SU11248 (sunitinib malate) therapy in patients with refractory metastatic breast cancer: preliminary safety and efficacy results from a phase II study by Miller, K.D., Burstein, H.J., Elias, A.D., Rugo, H.S., Cobleigh, M.A., Wolff, A.C., Eisenberg, P.D., Collier, M., Adams, B.J., Baum, C.M.

Get full text

Sources and sequelae of bacterial contamination of hematopoietic stem cell components: implications for the safety of hematotherapy and graft engineering by Webb, I J, Coral, F S, Andersen, J W, Elias, A D, Finberg, R W, Nadler, L M, Ritz, J, Anderson, K C

“…It is important to compare the incidence of bacterial contamination of components collected from the peripheral blood or bone marrow (BM), as well as of…”
Get more information

The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: An analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program by Elias, A.D, Ibrahim, J, Richardson, P, Avigan, D, Joyce, R, Reich, E, McCauley, M, Wheeler, C, Frei, E

“…Although high-dose chemotherapy (HDC) with stem cell rescue for the treatment of women with metastatic breast cancer (MBC) is currently a controversial…”
Get full text